Table 2.
Selected trials of adjuvant immunotherapy for resectable NSCLC.
| Trial name/NCT number | Phase | Stage | Regimen | Estimated sample Size | Primary endpoints | Median PFS |
|---|---|---|---|---|---|---|
| IMpower010 (NCT02486718) | III | IB‐IIIA | Atezolizumab | 1280 | DFS | 42.3 months |
| ANVIL (NCT02595944) | III | IB‐IIIA | Nivolumab | 903 | DFS and OS | Not reported |
| PEARLS (NCT02504372) | II | IB‐IIIA | Pembrolizumab | 1177 | DFS | Not reported |
| BTCRC LUN18‐ 153 (NCT04317534) | II | I | Pembrolizumab | NA | DFS | Not reported |
| NCT04585477 | II | I‐III | Durvalumab | 80 | Decrease in ctDNA level | Not reported |
| BR31 (NCT02273375) | III | IB‐IIIB | Durvalumab | 1415 | DFS | Not reported |
Abbreviation: NSCLC, non‐small cell lung cancer.